Form 4: Krystal Biotech Executive and Spouse Execute Pre-Planned Stock Sales

Suma Krishnan, President of R&D and a 10% owner of Krystal Biotech, along with her spouse, sold a combined total of 14,127 shares of common stock in early July 2025, pursuant to pre-arranged Rule 10b5-1 trading plans.

Summary

• Suma Krishnan, President of R&D, Director, and 10% Owner of Krystal Biotech, Inc. (KRYS), reported sales of common stock.
• On July 9, 2025, Suma Krishnan directly sold 200 shares of common stock at a weighted average price of $150.139 per share.
• On July 10, 2025, Suma Krishnan directly sold an additional 6,500 shares at a weighted average price of $150.2252 per share and 300 shares at an average price of $151.3867 per share.
• Following these transactions, Suma Krishnan directly beneficially owns 1,456,711 shares of common stock.
• Sales were also reported by Suma Krishnan's spouse, Krish S. Krishnan, who directly sold 200 shares on July 9, 2025, at an average price of $150.07 per share.
• The spouse further sold 6,627 shares on July 10, 2025, at a weighted average price of $150.2184 per share and 300 shares at an average price of $151.3867 per share.
• All reported sales by both Suma Krishnan and her spouse were executed pursuant to Rule 10b5-1 trading plans, which commenced on September 12, 2024, and are set to terminate on September 13, 2025.
• Suma Krishnan also indirectly beneficially owns 90,000 shares via SMK Trust, 50,000 shares via Krishnan Family Trust, and 1,525,929 shares directly owned by her spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under pre-arranged Rule 10b5-1 trading plans mitigates concerns about opportunistic selling and indicates a planned transaction rather than a reaction to new information. The insider also retains significant holdings.

Positives

• The sales were conducted under Rule 10b5-1 trading plans, indicating they were pre-scheduled and not based on new, non-public information, which enhances transparency and reduces concerns about opportunistic insider selling.
• The reporting person and her spouse retain significant beneficial ownership in Krystal Biotech, demonstrating continued alignment with shareholder interests.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although this is mitigated by the 10b5-1 plan.

Risks

• The primary risk is the potential for negative market perception associated with insider selling, despite the mitigating factor of the Rule 10b5-1 trading plan.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider stock transactions.

Management Comments

• The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024, and will terminate on September 13, 2025.
• The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024, and will terminate on September 13, 2025.

Industry Context

This Form 4 filing is specific to Krystal Biotech's insider trading activity and does not provide broader industry trends or competitive analysis. Insider transaction reports are standard disclosures for publicly traded companies across all industries.

Related Party Transactions

• Sales of common stock by Krish S. Krishnan, the spouse of the Reporting Person, are disclosed as indirect beneficial ownership for Suma Krishnan and constitute related party transactions.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive and a significant owner, even if pre-planned, could lead to minor short-term market reactions, but the volume is relatively small compared to total outstanding shares and the insider's remaining holdings.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued sales may occur under the existing Rule 10b5-1 trading plans until their termination date of September 13, 2025.

Key Dates

Keywords

Krystal Biotech, KRYS, Form 4, insider trading, stock sale, 10b5-1 plan, Suma Krishnan, biotech, pharmaceutical